Origin

Developed in the early 2000s. KTTKS mimics a bioactive fragment of type I procollagen that fibroblasts recognize; a palmitoyl fatty-acid tail was added for skin penetration. Classic 'matrikine' cosmetic strategy.

Mechanism

Triggers fibroblast matrikine signaling, activating TGF-β and boosting synthesis of collagen I/III, fibronectin, and glycosaminoglycans. Restores dermal support and reduces wrinkle depth.

Research summary

Evidence

Better cosmetic data than Snap-8, still thin next to pharmaceutical standards. Trials show significant wrinkle-depth improvement over 12 weeks in photoaged skin, but cohorts are small (20-60 participants) and industry-funded. Effect size: 10-20% wrinkle-depth reduction, roughly matching mild retinoids.

Evidence tier: Cosmetic ingredient (topical, unregulated as drug) — see the methodology note for how this is assessed.

Citations

Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin — Robinson et al. 2008

Reported benefits

reduced wrinkle depth and fine lines
improved skin elasticity/firmness
increased dermal hydration

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Topical serum/cream/moisturizer	2-5% palmitoyl pentapeptide-4 applied 1-2x daily; measurable improvement may take 8-12 weeks.

Side effects

minimal; rare local irritation/sensitization

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Common in anti-aging serums, often paired with vitamin C and retinoids. Seen as better-evidenced than Snap-8 but weaker than prescription retinoids.